Topics

Cytokine Polymerization: A Double-Edged Sword in Immune Regulation

“Cytokine polymerization” is not a single canonical biological pathway. In current therapeutic research, the phrase can encompass multimerizing a cytokine or ligand, attaching cytokines to polymeric carriers, or assembling cytokine-bearing nanoparticles and matrices. These designs seek to increase avidity, half-life, tissue retention, or receptor selectivity. They also create a double-edged form of immune regulation because higher-order presentation can transform weak, transient signaling into potent receptor clustering and systemic inflammation. Cytokine-engineering reviews and early work with a multimeric CD40 ligand show how molecular format changes biological activity. Precise terminology is therefore essential: oligomerization, polymer conjugation, and supramolecular delivery have different structures, mechanisms, and safety questions The label should never be used to imply that native cytokines generally form long, covalent polymers in normal immune signaling[1][2][3].

Cytokine receptors often signal through ligand-induced assembly and activation of associated kinases or adaptor proteins. Increasing valency can raise local concentration, stabilize receptor engagement, and cross a signaling threshold that soluble monomeric material does not reach. The multimeric CD40 ligand example produced strong immunostimulatory activity by creating an effective higher-order agonist. Polymer conjugation can instead enlarge hydrodynamic size, slow clearance, shield a protein, or release it in response to local conditions. Targeting domains may bias activity toward tumor, lymphoid tissue, or a selected immune cell. These benefits depend on preserved protein conformation and controlled spacing; uncontrolled aggregation can reduce activity, provoke antibodies, or trigger complement and off-target receptor activation Geometry matters because two constructs with the same cytokine mass can generate different receptor assemblies, trafficking behavior, and downstream transcription[1][2][3].

Applications include concentrating IL-2- or IL-12-like activity in tumors, presenting costimulatory ligands to antigen-presenting cells, and delivering anti-inflammatory cytokines to diseased tissue. Multivalent formats may reduce dosing frequency or preferentially activate receptor configurations associated with desired cells. Conversely, excessive receptor clustering can produce cytokine release, vascular leak, hepatic injury, or broad immune-cell activation. A long-circulating carrier may prolong toxicity as well as efficacy, and biodegradation products can alter inflammation. Manufacturing introduces additional variables: size distribution, cytokine loading, free protein, aggregation, and release kinetics all influence dose. “More stable” or “more multivalent” is therefore not automatically therapeutically superior Tumor targeting may improve exposure ratios, yet target shedding or heterogeneous expression can redirect a multivalent construct away from intended cells[1][2].

Research should define each construct structurally before drawing mechanistic conclusions. Studies need quantitative relationships among valency, spacing, receptor occupancy, signaling duration, tissue exposure, and functional outcome. Head-to-head comparisons with the unmodified cytokine should separate delivery effects from true signaling bias. Human immune-cell assays and relevant toxicology models are essential because cytokine receptors and sensitivity can differ across species. Reversible, locally activated, or biodegradable systems may preserve potency while limiting systemic persistence. Cytokine polymerization can become a valuable engineering principle, but only when higher-order assembly is treated as a controllable pharmacologic variable rather than a generic method for making immune stimulation stronger Pharmacokinetic and pharmacodynamic models must treat carrier-bound, released, aggregated, and degraded cytokine as distinct species rather than one nominal dose. Clear nomenclature will also let regulators compare constructs by physical form, exposure, and mechanism instead of an ambiguous platform label[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
536
HY-13417A AICAR phosphate
AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor.

Source: Body

231
HY-100941 CCCP
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
192
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

178
HY-B0240 Disulfiram
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
161
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
147
HY-B0141C Estradiol hemihydrate
Estradiol (β-Estradiol) hemihydrate is a steroid hormone and the major female sex hormone. Estradiol (β-Estradiol) hemihydrate can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol (β-Estradiol) hemihydrate can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
141
HY-B0141 Estradiol
Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
141
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
88
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
87
HY-L008 JAK/STAT Compound Library
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 738 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.
86
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
84
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
83
HY-L131 Osteogenesis Compound Library
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health. Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc. MCE offers a unique collection of 984 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.
83
HY-L132 Chemokine Compound Library
Chemokines, or chemotactic cytokines, are small cytokines or signaling proteins secreted by cells. They are a component of intercellular communication, controlling the directional movement of immune cells especially leukocytes, as well as other cell types, for instance, endothelial and epithelial cells, which are essential to maintain human health and the function of the immune system. The biological effects of chemokines are achieved by binding to chemokine receptors, which are G protein-coupled receptors found on the surface of leukocytes. Some chemokine receptors are involved in directing tumor metastasis and over-expression by certain tumors. So inhibiting the interaction between chemokine and chemokine receptors on the surface of tumor cells may be a new possible therapeutic approach. Some chemokine receptors are coreceptors for HIV entry, and related inhibitors have been approved by the FDA to treat patients with HIV. Obviously, chemokines and chemokine receptors have become new targets for studying cancer, HIV, inflammation, and other diseases. MCE supplies a unique collection of 257 chemokine or chemokine receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on chemokine or chemokine receptors. MCE Chemokine Library is a useful tool for drug research related to cancer, AIDS, and wound therapy.
83
HY-L150 Membrane Receptor-targeted Compound Library
Membrane receptors, also known cell surface receptors or transmembrane receptors, are transmembrane proteins embedded into the plasma membrane which play an essential role in maintaining communication between the internal processes within the cell and various types of extracellular signals. They act in cell signaling by receiving (binding to) extracellular molecules, which are also called ligands. These extracellular molecules include hormones, cytokines, growth factors, neurotransmitters, lipophilic signaling molecules such as prostaglandins, and cell recognition molecules. There are three kinds of membrane receptors: ion channel-linked receptors, enzyme-linked receptors and G-protein-linked receptors. They play important roles in keeping human normal physiologic processes. GPCRs and ion channels are important drug targets in drug discovery. MCE provides a unique collection of 7,133 compounds targeting a variety of membrane receptors. MCE Membrane reeptor-targeted Compound Library can be used for membrane receptor-focused screening and drug discovery.
83
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.
83
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
83
HY-L175 Inflammasomes related Compound Library
Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response. MCE designs a unique collection of 178 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
83
HY-L185 Anti-Fibrosis Compound Library
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 2,568 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.
83
HY-L194 Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
Heat-clearing and detoxification is a specific treatment method in the research of traditional Chinese medicine (TCM), which is clinically used to treat infectious diseases with remarkable effect. Over the past decades, the research of heat-clearing and detoxification treatment has been one of the most active fields of combining traditional Chinese and western medicines, and has made remarkable achievements. Nowadays, the application field of heat-clearing and detoxification traditional Chinese medicine is not only limited to antibacterial and antiviral, but also has made progress in the research fields of anti-inflammatory reaction, anti-endotoxin, anti-peroxidative damage, anti-inflammatory cytokines, enhancement of immune function, protection of cellular organelles, and maintenance of calcium homeostasis. In addition to this, clearing heat and removing toxins has also made significant research progress in non-infectious diseases, for example, in tumors, cardiovascular diseases, renal diseases, blood diseases, geriatrics, and diabetes, all of which have shown good curative effect. MCE can supply 1,282 monomer component from more than a hundred sources of heat-clearing and detoxification TCM, which can be used in TCM studies, drug development and mechanism-based studies.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L216 Polysaccharides Compound Library
Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development. MCE offers 70 polysaccharides that can be used in biomedical studies.
83
HY-L258 Alkyne Compound Library
In modern medicinal chemistry and chemical biology research, alkyne (-C≡C-) structures play an important role in click chemistry, bioorthogonal labeling, and the construction of functional molecules due to their unique linear geometry and high reactivity. In particular, driven by the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC) and copper-free click reactions (SPAAC), terminal alkyne groups have become important “chemical handles” for building complex biomolecular systems. The MCE Alkyne Compound Library contains 437 compounds designed for the construction of click chemistry reaction systems and the development of diverse functional molecules. In drug discovery, these structures serve as key reactive sites that can efficiently undergo click reactions with azide groups, enabling modular assembly of PROTAC molecules, construction of ADC linkers, and rapid synthesis of bioorthogonal labeling probes. In addition, alkyne groups exhibit high stability, mild reaction conditions, and excellent biocompatibility, allowing them to maintain reactivity in complex biological environments. This contributes to improved efficiency and controllability in drug development, making them indispensable chemical building blocks in modern drug design and functional molecular engineering.
83
HY-L937 Unnatural Amino Acids Fragment library
Unnatural amino acids (UAAs), also referred to as non-canonical amino acids (ncAAs) or non-proteinogenic amino acids, are a class of amino acids that are distinct from the 20 standard natural amino acids. They can be obtained through chemical synthesis, biosynthesis, and other approaches, with structural diversity far exceeding that of natural amino acids. UAAs are mainly including naturally occurring non-canonical amino acids, chemically synthesized amino acids, and biosynthetic amino acids, which provide a molecular basis for protein function design. UAAs exhibit significant value in multiple fields. They can optimize the pharmacokinetic properties of peptide drugs and peptidomimetics, modify enzyme functions and endow them with new biological activities, thereby overcoming the limitations of traditional peptide drugs and expanding the chemical space . Meanwhile, UAAs can serve as molecular probes to analyze protein-protein interactions and investigate the regulatory mechanisms of protein functions. MCE has compiled a UAAs Fragment Library comprising nearly a thousand unnatural amino acid fragments with extensive coverage of chemical space and enhanced structural diversity. This compound library can be widely applied in peptide synthesis, drug design, and protein engineering.
83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
83
HY-10964 Vadimezan
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
80
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
74
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
73
HY-A0003 Lenalidomide
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
63
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

57
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
50
HY-100564A 2',3'-cGAMP sodium
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
44
HY-100564 2',3'-cGAMP
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
44
HY-117287 Deucravacitinib
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
36
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
35
HY-B2247 PLGA (50:50)
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.
32
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

30
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

20
HY-134581 Enpatoran
Enpatoran (M5049) is an orally active and selective TLR7/8 antagonist. Enpatoran inhibits the activation of the downstream type I interferon pathway. Enpatoran is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis.
18
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
16
HY-P1860 TNF-α (31-45), human
TNF-α (31-45), human is a potent NF-kB pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis.
13
HY-P9926 Dupilumab
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.

Species: Human

9
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
8
HY-147124 RIG012
RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
IFNAR  
Cancer   Infection  
6
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
6
HY-P99168 Anifrolumab
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

Species: Human

5
HY-N0474 Tyrosol
Tyrosol is a derivative of phenethyl alcohol. Tyrosol attenuates pro-inflammatory cytokines from cultured astrocytes and NF-κB activation. Anti-oxidative and anti-inflammatory effects.
4
HY-N0609 Cinnamaldehyde
Cinnamaldehyde is a major and a bioactive compound isolated from the leaves of Cinnamomum osmophloeum kaneh. Cinnamaldehyde is a cytokine production inhibitor. Cinnamaldehyde has anti-bacteria, anti-oxidation, and anti-inflammatory properties.
3
HY-Y0344J Sodium chloride, for molecular biology
Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells.
3
HY-Y0344D Sodium chloride, for cell culture
Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells.
3
HY-P990034 Pateclizumab
Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis.

Species: Human

2
HY-P99008 Atibuclimab
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury.

Species: Human

2
HY-B0141R Estradiol (Standard)
Estradiol (Standard) is the analytical standard of Estradiol. This product is intended for research and analytical applications. Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
2
HY-P72907 CD40L/CD154/TRAP Protein, Human (His)
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in human, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Protein, Human (His) has a total length of 144 amino acids (E108-L261), is expressed in E. coli cells with C-terminal His-tag.

Species: Human; Source: E. coli

2
HY-13740S Resiquimod-d5
Resiquimod-d5 is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
1
HY-P99342 Imdevimab
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins.

Species: Virus

1
HY-N2083 Handelin
Handelin is a guaianolide dimer from Chrysanthemum boreale that has potent anti-inflammatory activity by down-regulating NF-κB signaling and pro-inflammatory cytokine production.
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

1
HY-13417S AICAR-13C2,15N
AICAR-13C2,15N (Acadesine-13C2,15N; AICA Riboside-13C2,15N) is the 13C and 15N labeled AICAR (HY-13417). AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and mitophagy inhibitor.
/
HY-P1796A Gp100 (619-627) acetate
Gp100 (619-627) acetate is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.
/
HY-143686 ImmTher
ImmTher is a liposome-encapsulated lipophilic disaccharide tripeptide derivative of muramyl dipeptide. ImmTher can up-regulate specific monocyte cytokine genes and activate monocyte-mediated tumoricidal activity.
/
HY-B0174AS3 Olsalazine-d6
Olsalazine-d6 is the deuterium labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
/
HY-B0966S Dioxybenzone-d3
Dioxybenzone-d3 is deuterium labeled Dioxybenzone. Dioxybenzone (Benzophenone-8; UV-24) is an organic compound used to block UVB and short-wave UVA (ultraviolet) radiation. Dioxybenzone has orally activity. Dioxybenzone exhibits estrogenic disrupting effect. Dioxybenzone up-regulates inflammatory cytokines. Dioxybenzone can be used for cancer, reproductive system disease and inflammatory disease study.
/
HY-B0174AS Olsalazine-13C6
Olsalazine-13C6 is the 13C labeled Olsalazine (HY-B0174A). Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic.
/
HY-P1796 Gp100 (619-627)
Gp100 (619-627) is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy.
Others  
Cancer  
/
HY-P990083A Tegoprubart (powder)
Tegoprubart (powder) (AT-1501 (powder)) is a CD40 ligand inhibitor (EC50=100 ng/mL) and immunosuppressant that selectively inhibits the CD40 ligand, a co-stimulatory molecule involved in T cell activation. Tegoprubart (powder) suppresses immune rejection, prevents rejection in animal transplantation models, and reduces cell-mediated and antibody-mediated immune responses to create a more immunotolerant environment. Tegoprubart (powder) preserves renal function when combined with Mycophenolate (HY-B0421) and Corticosteroids, and maintains graft function in preclinical studies. Tegoprubart (powder) is applicable to research related to kidney transplantation and kidney transplant rejection.
/
HY-P3728 Interleukin II (60-70)
Interleukin II (60-70) is a 60-70 fragment of the cytokine Interleukin II polypeptide.
/
HY-N3487 Isodorsmanin A
Isodorsmanin A is an anti-inflammatory agent. Isodorsmanin A suppresses the production of inflammatory mediators and proinflammatory cytokines. Isodorsmanin A inhibits the phosphorylation of JNK, MAPK.
/
HY-P11253 DOTA-Bn-CA-170
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
/
HY-19717S DCVC-13C3,15N
DCVC-13C3,15N is 15N and 13C labeled DCVC. DCVC (S-[(1E)-1,2-Dichloroethenyl]-L-cysteine) is a bioactive metabolite of trichloroethylene (TCE). DCVC inhibits pathogen-stimulated pro-inflammatory cytokines IL-1β, IL-8, and TNF-α release from tissue cultures.
/
HY-NP077A Phaseolus vulgaris Lectin-P
Phaseolus vulgaris Lectin-P is the protein form of Phytohemagglutinin before the separation and purification of Phytohemagglutinin-L (PHA-L) and PHA-E. Phaseolus vulgaris Lectin-P can be used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins.
/
HY-P992342 DCB-8
DCB-8 is a specific inhibitor targeting human TIM-3. DCB-8 regulates T cell function, enhances cytokine secretion, and inhibits tumor growth in disease animal models. DCB-8 can be used for cancer research.

Species: Human

Tim3  
Cancer  
/
HY-P1828 EGFRvIII peptide (PEPvIII)
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P4054 IEIK 13
IEIK 13 is a self-assembling peptide (SAP) sequence. IEIK 13 can be used for the research of cartilage tissue engineering
Others  
/
HY-P10293 NQEQVSP
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization.
Thrombin   Others  
/
HY-NP077B Phaseolus vulgaris Lectin-M
Phaseolus vulgaris Lectin-M is a sticky protein form of lectin. Phaseolus vulgaris Lectin-M is mainly used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins 。
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
/
HY-P992061 Anti-Mouse CD3E Antibody (500A2)
Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes.

Species: Mouse

/
HY-B2162H Chondroitin sulfate (from fish)
Chondroitin sulfate (from fish), one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate (from fish) reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS and MMPs.
/
HY-149773S HPK1-IN-40-d2
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC50 of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity.
/
HY-P992051 Anti-CD103 Antibody (hCD103.01A)
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

/
HY-16900G Rolipram (GMP)
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
/
HY-P991529 AGEN-2373
AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies.

Species: Human

/
HY-P11355 KRAS WT Peptide
KRAS WT Peptide is the normal sequence peptide of the Kirsten rat sarcoma virus (KRAS) gene without oncogenic mutations. KRAS WT Peptide can be used for the study of evaluating the specificity and safety of KRAS-targeted immunotherapies.
Others  
Cancer  
/
HY-101112 Okicenone
Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation.

Source: Streptomyces

/
HY-P3831 β-Interleukin II (44-56)
β-Interleukin II (44-56) is a 44-56 fragment of beta-interleukin II polypeptide. Interleukin family are a group of cytokines associated with immune system, mainly expressed by leukocytes.
/
HY-P10432 SHAAGtide
SHAAGtide is a FPRL1 activator. SHAAGtide has anti-inflammatory activity, mediates its biological activity via FPR2 and is used to reduce the expression of inflammatory cytokines in mouse models. SHAAGtide can be used in the study of diseases such as lung inflammation and fibrosis.
/
HY-P0071 F 991
F 991 is an immunoglobulin free light chain antagonist. F 991 can significantly reduce the levels of pro-inflammatory cytokines (TNF-α and IL-6). F 991 can be used for research on allergic conditions.
/
HY-10978S Crisaborole-d4
Crisaborole-d4 is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.
/
HY-P11296 LLVK
LLVK is a selective IκB phosphorylation inhibitor. LLVK reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK is promising for research of inflammatory bowel disease and rheumatoid arthritis.
/
HY-N3788 Dulcioic acid
Dulcioic acid (compound 19) is a product isolated from Tripterygium wilfordii Hook f. Dulcioic acid shows a significant inhibitory effect on cytokine production.
/
HY-P991557 ABI793
ABI793 is a human IgG1 anti-human CD154 (CD40 ligand) monoclonal antibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection.

Species: Human

/
HY-P991634 IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.

Species: Human

/
HY-116705G 2-Deoxy-2-fluoro-L-fucose (GMP)
2-Deoxy-2-fluoro-L-fucose (2-Fluorofucose) GMP is a fucosyltransferase inhibitor that inhibits core fucosylation modification in cells. 2-Deoxy-2-fluoro-L-fucose GMP promotes the production of defucosylated IgG1 antibodies in IgG1-expressing cell culture systems; it regulates the levels of inflammatory cytokines such as IL-1β, IL-6 and TGF-β in human induced pluripotent stem cell-derived microglia. 2-Deoxy-2-fluoro-L-fucose GMP can be used in the research of related diseases including dengue fever and Alzheimer's disease.
/
HY-P10417 RTDLDSLRTYTL
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
Integrin   IFNAR  
Cancer  
/
HY-P5350 FN-A208 fusion peptide
FN-A208 is a biological active peptide. (This peptide is a fusion of A208, derived from murine laminin a1, and the active site of fibronectin (GRGDS), with a glycine spacer. This peptide forms amyloid-like fibrils and promotes formation of actin stress fibers that mediate fibroblast cell attachment, offering it potential as a bioadhesive for tissue regeneration and engineering. FN-A208 interacts with IKVAV receptors and integrins. Its activity is disrupted by the presence of EDTA.)
Others  
/
HY-P991654 SAR228810
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.

Species: Human

/
HY-P2642 Peptide 78
Peptide 78, a chemotactic cytokine, a 78 amino acid protein member of the IL-8 or C-X-C chemokine supergene family. ENA-78 plays an important role in the elicitation of predominantly neutrophils (PMNs) into the joints of rheumatoid arthritis (RA).
/
HY-P992182 ANB032
ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].

Species: Human

/
HY-177130S Socrodeucitinib
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC50 value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases.
/
HY-D3190 BODIPY−DOX
BODIPY-DOX is a conjugate composed of BODIPY and Doxorubicin (HY-15142A), as well as a pH-activated fluorescent probe for M1 macrophages and an apoptosis inducer. BODIPY-DOX undergoes pH-induced hydrazone bond cleavage in acidic M1 macrophage phagosomes, thereby releasing cytotoxic Doxorubicin (Dox) and inhibiting the function of pro-inflammatory M1 macrophages. BODIPY-DOX highly selectively inhibits the production of relevant pro-inflammatory cytokines by mouse and human monocyte-derived M1 macrophages, while exerting minimal effects on M2 or unactivated macrophages. Therefore, BODIPY-DOX enables simultaneous fluorescent tracing, differentiation and elimination of specific macrophage subsets, and exhibits the potential to regulate tissue regeneration in zebrafish models.
/
HY-P3912 Endotoxin inhibitor
Endotoxin inhibitor a synthetic peptide that binds lipid A with high affinity, thereby detoxifying LPS (HY-D1056) and preventing LPS-induced cytokine release in vivo. Endotoxin inhibitor inhibits the febrile response to LPS with very low toxicity and lethality.
/
HY-D2630 Cy3 HA MA (MW 3000)
Cy3 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
/
HY-N15322 Polyandric acid A
Polyandric acid A is a clerodane diterpenoid that can be isolated from the Australian medicinal plant D. polyandra. Polyandric acid A attenuates pro-inflammatory cytokine secretion.
/
HY-W013021R Norbornene (Standard)
Norbornene (Standard) is the analytical standard of Norbornene (HY-W013021). This product is intended for research and analytical applications. Norbornene is a bicyclic compound. Norbornene polymers can be used in tissue engineering and drug release system.
/
HY-D2651 Cy5 HA MA (MW 50000)
Cy5 HA MA (MW 50000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 50000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
/
HY-D2649 Cy5 HA MA (MW 5000)
Cy5 HA MA (MW 5000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 5000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
/
HY-D2681 Cy7 HA MA (MW 3000)
Cy7 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY7 (HY-D0825). Cy7 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 740/770 nm).
/
HY-D2632 Cy3 HA MA (MW 10000)
Cy3 HA MA (MW 10000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 10000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
/
HY-N0976 1,11b-Dihydro-11b-hydroxymedicarpin
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative. Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways. Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice.
/
HY-D2633 Cy3 HA MA (MW 50000)
Cy3 HA MA (MW 50000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 50000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
/
HY-126042S4 (±)-Lisofylline-d4
(±)-Lisofylline-d4 ((±)-Lisophylline-d4) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research.
/
HY-158726 Complex 3
Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC50 values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume in an AsPC-1 mouse xenograft model.
/
HY-141432G NX-1607 (GMP)
NX-1607 (Cbl-b-IN-3) (GMP) is a GMP-grade NX-1607 (HY-141432). GMP-grade small molecules can be used as adjuvant agents in cell therapy. NX-1607 (GMP) enhances antigen recall, reduces T cell exhaustion and increases cytokine production. NX-1607 is an inhibitor of Cbl-b (an E3 enzyme).
/
HY-D2650 Cy5 HA MA (MW 10000)
Cy5 HA MA (MW 10000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 10000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
/
HY-D2634 Cy3 HA MA (MW 100000)
Cy3 HA MA (MW 100000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 100000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
/
HY-D2648 Cy5 HA MA (MW 3000)
Cy5 HA MA (MW 3000) is a hyaluronic acid methacrylate labeled with CY5 (HY-D0821). Cy5 HA MA (MW 3000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 633/670 nm).
/
HY-D2631 CY3 HA MA (MW 5000)
Cy3 HA MA (MW 5000) is a hyaluronic acid methacrylate labeled with CY3 (HY-D0822). Cy3 HA MA (MW 5000) is widely used in the fields of biolabeling and imaging, drug delivery and tissue engineering and regenerative medicine (Ex/Em = 550/570 nm).
/
HY-N6770 Curvularin
Curvularin, a fungal metabolite and a potent mycotoxin naturally isolated from Curvularia lunata, inhibits cytokine-induced nitric oxide synthase (iNOS), with an IC50 of 9.5 µM.

Source: fungus Eupenicillium sp

/
HY-121892 (Z)-KC02
(Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo.
/
HY-N6878 Cauloside D
Cauloside D is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside D exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines.
/
HY-P11355A KRAS WT Peptide TFA
KRAS WT Peptide TFA is the trifluoroacetate salt of KRAS WT Peptide (HY-P11355). KRAS WT Peptide is the normal sequence peptide of the Kirsten rat sarcoma virus (KRAS) gene without oncogenic mutations. KRAS WT Peptide can be used for the study of evaluating the specificity and safety of KRAS-targeted immunotherapies.
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

/
HY-P991125 Cenzestotug
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.

Species: Human

/
HY-D1236 Fluorescent brightener 71
Fluorescent brightener 71 (FB71) is an inhibitor targeting deubiquitinases UCHL5 and USP14, as well as a CD40 ligand. Fluorescent brightener 71 blocks enzymatic activity, induces apoptosis, inhibits cell growth and triggers reactive oxygen species production. Meanwhile, Fluorescent brightener 71 upregulates the expression of oxidative stress-related genes gpx-4 and sod-4, and reversibly increases the protein levels of UCHL5 and USP14 through a feedback response. Fluorescent brightener 71 inhibits the growth, movement and reproductive capacity of Caenorhabditis elegans, and also exhibits concentration-dependent toxic effects. Fluorescent brightener 71 can be applied to scientific research in related fields such as breast cancer.
/
HY-122767 Romurtide
Romurtide (Muroctasin), a synthetic muramyl dipeptide derivative, is a cytokines inducer. Romurtide can increase peripheral neutrophils and monocytes in vivo and enhance production of colony-stimulating factors (CSFs), IL-1 and IL-6 in vitro.
/
HY-148775 PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma.
/
HY-W415798 Ac4GalNAlk
Ac4GalNAlk is a weakly alkyne-labeled reagent for metabolic oligosaccharide engineering (MOE) that can be used to detect protein glycosylation. MOE reagents can be activated by cellular biosynthetic machinery into nucleotide sugars, which can be further traced through the introduction of glycoproteins in bioorthogonal chemistry. Ac4GalNAlk promotes nucleotide-sugar biosynthesis and increases bioorthogonal cell surface markers.
/
HY-P992112 Eliroptamig
Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing.

Species: Human

/
HY-W145695 Chitoheptaose
Chitoheptaose is an orally active chitooligosaccharide (degree of polymerization = 7). Chitoheptaose can be extracted from the exoskeletons of crustaceans, such as the shells of crabs, shrimps and lobsters. Chitoheptaose reduces pro-inflammatory cytokines while increasing the levels of anti-inflammatory cytokines (decreasing the levels of pro-inflammatory cytokines IL-1β, IL-17A and IFN-γ, and increasing the level of the anti-inflammatory cytokine IL-10). Chitoheptaose possesses antioxidant, anti-inflammatory and anti-Apoptotic activities. Chitoheptaose improves cardiac parameters, alleviates myocarditis injury, and exerts cardioprotective effects in a rat model of myocarditis. Chitoheptaose can be used in studies related to myocarditis.
/
HY-136512 Streptazolin
Streptazolin is an antibiotic. Streptazolin increases bacterial killing and elaboration of immunostimulatory cytokines by macrophages in vitro. Streptazolin stimulates the macrophage NF-κB pathway via PI3K signaling.

Source: Streptomyces viridochromogenes

/
HY-117123 Convulxin
Convulxin is a toxin found in a tropical rattlesnake. Convulxin stimulates platelet aggregation, and clusters GPVI to trigger Src family kinase activation, Fc receptor γ chain phosphorylation, and p72SYK signaling. Convulxin interacts with Dectin-2 to induce IL-10 production, activates monocytes to generate ROS and NLRP3 inflammasome-mediated IL-1β secretion, and induces mitochondrial ROS. Convulxin causes transient arterial blood pressure changes in dogs. Convulxin can be used for research related to coagulation.

Source: Crotalus durissus terrificus

/
HY-P2263A KLD-12 TFA
KLD-12 TFA is the TFA salt form of KLD-12 (HY-P2263). KLD-12 TFA is a self a 12-residue self-assembling peptide that is used in tissue-engineering. KLD-12 TFA combined with SDF-1 self-assembled polypeptide enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 TFA hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.
/
HY-P991525 2141-V11
2141-V11 is an Fc-engineered agonistic antibody against human CD40 with selectively enhanced binding affinity for human FcγRIIB. 2141-V11 drives CD40 multimerization and agonistic signal transduction, activates dendritic cells, promotes antigen cross-presentation and CD8+ T cell priming, induces tertiary lymphoid structure formation, increases leukocyte infiltration, and mediates local and abscopal anti-tumor effects, systemic immune activation and immune memory. 2141-V11 exhibits extremely low systemic toxicity upon intratumoral or intravesical administration, with no dose-limiting toxicity observed at the tested intratumoral doses, whereas high-dose systemic administration induces thrombocytopenia and elevated transaminases. 2141-V11 can be used in research related to breast cancer, melanoma, BCG-unresponsive non-muscle invasive bladder cancer, and recurrent malignant glioma.

Species: Human

/
HY-P99704 Licaminlimab
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation.

Species: Human

/
HY-P99825 Relfovetmab
Relfovetmab is a monoclonal antibody and also serves as a single-chain variable fragment component for engineering chimeric antigen receptors (CAR) in modified CAR-T cells. Relfovetmab can be used in studies of cancer and immune disorders.

Species: Feline

/
HY-P99431 KY-1044
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response.

Species: Human

/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P990901 Aplitabart
Aplitabart (IGM-8444) is a pentameric IgM death receptor 5 (DR5) agonist antibody with a KD of 85 nM and an apparent affinity of 11 pM. Aplitabart induces DR5 multimerization, thereby triggering cancer cell apoptosis via the extrinsic apoptotic pathway apoptosis. Aplitabart is applicable to cancer-related research such as colorectal cancer and gastric cancer.

Species: Human

/
HY-P10493A NY-ESO-1 (157-165) peptide TFA
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
/
HY-158222 Alginate Methacryloyl (MW 50000)
Alginate Methacryloyl (MW 50000) is a methacryloyl alginate with potential for use as a tissue engineering scaffold and 3D printing ink. Alginate Methacryloyl (MW 50000) is biocompatible, non-immunogenic, has low toxicity and is capable of physical cross-linking with divalent cations such as calcium. Alginate Methacryloyl (MW 50000) needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.
/
HY-P2263 KLD-12
KLD-12 is a 12-residue self-assembling peptide that is used in tissue-engineering. KLD-12 combined with SDF-1 self-assembled polypeptide enhances chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.
/
HY-W110542D Poly(ethylene glycol) diacrylate (MW 1000)
Poly(ethylene glycol) diacrylate (PEGDA) (MW 1000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine.
/
HY-D1005A2 Poloxamer 105 (L35)
Poloxamer 105 L35 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1900 Da. Poloxamer 105 L35 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering.
/
HY-P10089 TREM-1 inhibitory peptide M3
TREM-1 inhibitory peptide M3 is a ligand-dependent TREM-1 antagonist. TREM-1 inhibitory peptide M3 can inhibit systemic and pulmonary pro-inflammatory cytokine and chemokine production and attenuate acute lung injury.
/
HY-P99605 Cinrebafusp alfa
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research.
EGFR   TNF Receptor  
Cancer  
/
HY-P990095 Vonsetamig
Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma.

Species: Human

/
HY-P991336 Ordastobart
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.

Species: Human

/
HY-158225 Methacrylated Type I collagen
Methacrylated Type I collagen (Col1MA) is a methacrylated tissue engineering scaffold material that retains the basic properties of natural collagen. Methacrylated Type I collagen needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.
MMP  
/
HY-W110542J Poly(ethylene glycol) diacrylate (MW 700)
Poly(ethylene glycol) diacrylate (PEGDA) (MW 700) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 700) mimics the extracellular matrix (ECM), providing support and growth space for cells.
/
HY-B1648 Ferric pyrophosphate
Ferric pyrophosphate is an orally effective anti-inflammatory agent and iron fortifier. Ferric pyrophosphate downregulates the expression of colonic pro-inflammatory cytokines, modulates the intestinal flora, and corrects the dysbiosis associated with iron deficiency anemia (IDA). Ferric pyrophosphate can be used in studies related to iron deficiency anemia.
/
HY-P99325 Toralizumab
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease.

Species: Human

/
HY-P99257 Bleselumab
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection.

Species: Human

/
HY-P991201 REGN-7257
REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases. Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).

Species: Human

/
HY-P10580A Vasculotide TFA
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.
/
HY-W145516 Guar gum
Guar gum is an orally active nonionic galactomannan polysaccharide. It is present in the endosperm of Cyamopsis tetragonolobus seeds. Guar gum reduces cholesterol levels, regulates body weight, and acts as a thickener and viscosity modifier by forming hydrogen-bonded aqueous solutions. It serves as a rate-controlling excipient in compound delivery systems, and finds applications in the food, tissue engineering, nanosensing and industrial fields.
/
HY-P99304 Lumretuzumab
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody. Lumretuzumab effectively inhibits the activity of key oncogenic signaling pathways such as PI3K/AKT and MAPK. Lumretuzumab has been optimized through glycosyl engineering to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Lumretuzumab can be used to study HER3-positive, HER2-low-expressing solid tumors, especially breast cancer.

Species: Human

EGFR   PI3K   Akt   p38 MAPK  
/
HY-P10580 Vasculotide
Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.
/
HY-P990083 Tegoprubart
Tegoprubart (AT-1501) is a CD40 ligand inhibitor (EC50=100 ng/mL) and immunosuppressant that selectively inhibits the CD40 ligand, a co-stimulatory molecule involved in T cell activation. Tegoprubart suppresses immune rejection, prevents rejection in animal transplantation models, and reduces cell-mediated and antibody-mediated immune responses to create a more immunotolerant environment. Tegoprubart preserves renal function when combined with Mycophenolate (HY-B0421) and Corticosteroids, and maintains graft function in preclinical studies. Tegoprubart is applicable to research related to kidney transplantation and kidney transplant rejection.

Species: Human

/
HY-P10493 NY-ESO-1 (157-165) peptide
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy.
/
HY-158229 Heparin Methacrylate
Heparin Methacrylate (HepMA) is methacrylated heparin and is an ideal tissue engineering scaffold material and 3D printing bioink. Heparin Methacrylate needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.
/
HY-W110542G Poly(ethylene glycol) diacrylate (MW 6000)
Poly(ethylene glycol) diacrylate (PEGDA) (MW 6000) is a versatile polymer material that is widely used as a building material for hydrogel scaffolds, especially in the fields of tissue engineering and regenerative medicine. Poly(ethylene glycol) diacrylate (MW 6000) can be used as a building material for wound dressing hydrogels.
/
HY-23119 Sodium thiocyanate, GR, 99%
Sodium thiocyanate reduces plasma levels of the pro-inflammatory cytokine IL-6, and increases the anti-inflammatory cytokine IL-10 levels. Sodium thiocyanate also significantly reduces of ROS formation.

Source: milk

/
HY-P5558 KLTWQELYQLKYKGI
KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair.
/
HY-P9945 Mepolizumab
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.

Species: Human

/
HY-D1005A6 Poloxamer 124 (L44)
Poloxamer 124 L44 is a block polymer of polyoxyethylene and polyoxypropylene and a hydrophobic surfactant. Poloxamer 124 L44 causes eye irritation and exhibits oral toxicity in albino rats with an LD50 of 5 g/kg. Poloxamer 124 L44 has reversible adverse effects on triglyceride and cholesterol transport in the lymphatic system of rats. Poloxamer 124 L44 can form thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering[1][2][3].
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

/
HY-W110584 Carboxybetaine methacrylate
Carboxybetaine methacrylate is an amphoteric ionic compound with excellent properties such as good hydrophilicity, antistatic property, and biocompatibility. Carboxybetaine methacrylate can be used to prepare tissue engineering scaffolds, drug carriers, and so on.
/
HY-P99625 Frexalimab
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research.

Species: Human

/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

/
HY-P10587 Icotrokinra
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
/
HY-P70609 CD40L/CD154/TRAP Protein, Human (HEK293)
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in human, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). GMP CD40L/CD154/TRAP Protein, Human (HEK293) has a total length of 149 amino acids (M113-L261), is expressed in HEK392 cells under GMP standard with tag free.

Species: Human; Source: HEK293

/
HY-P71389 TSLP Receptor Protein, Human (HEK293, His)
TSLP Receptor Protein, a receptor for TSLP, forms a functional complex with IL7R, activating STAT3 and STAT5 for cell proliferation. It also activates JAK2, aiding in hematopoietic system development. TSLP Receptor forms a heterodimer with CRLF2 and IL7R, highlighting its role in intricate signaling pathways crucial for cellular responses and hematopoietic development. TSLP Receptor Protein, Human (HEK293, His) is the recombinant human-derived TSLP Receptor protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

/
HY-P78425 CD40L/CD154/TRAP Trimer Protein, Human (HEK293, His-Flag)
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in human, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Trimer Protein, Human (HEK293, His-Flag)  is composed of a full-length monomer of 149 amino acids (M113-L261), is expressed in HEK392 cells with N-terminal His- and Flag-tag.

Species: Human; Source: HEK293

/
HY-P79001 Crlf1 Protein, Mouse (HEK293, His, solution)
Crlf1 protein combines with CLCF1 to form an important neurotrophic cytokine involved in neuronal development. It plays a crucial role in the initiation and maintenance of lactation in neonatal mice and is associated with immune system regulation. Crlf1 Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived Crlf1 protein, expressed by HEK293 , with His labeled tag.

Species: Mouse; Source: HEK293

/
HY-P78271 CD40L/CD154/TRAP Trimer Protein, Mouse (HEK293, Fc)
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in mouse, cleaved into 2 chains of membrane form (1-260 a.a.) and soluble form (112-260 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Trimer Protein, Mouse (HEK293, Fc) has a total length of 149 amino acids (M112-L260), is expressed in HEK392 cells with N-terminal hFc-tag.

Species: Mouse; Source: HEK293

/
HY-P72122 CD40L/CD154/TRAP Protein, Rabbit (His)
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in Rabbit, cleaved into a soluble form, acts as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Protein, Rabbit (His) has a total length of 149 amino acids (M113-L261), is expressed in E. coli cells with N-terminal 6*His-tag.

Species: Rabbit; Source: E. coli

/
HY-P700842 TSLP Receptor Protein, Cynomolgus (HEK293, His)
TSLP Receptor protein is the receptor of TSLP and cooperates with IL7R to form a complex that activates STAT3 and STAT5 to stimulate cell proliferation. This receptor also activates JAK2, which is critical for the development of the hematopoietic system. TSLP Receptor Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TSLP Receptor protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

/
HY-P77583 CYTL1 Protein, Human (HEK293, hFc)
CYTL1 protein is specifically expressed in CD34+ hematopoietic cells, indicating that it exists selectively in this hematopoietic cell subpopulation. This targeted expression pattern suggests a potential role in maintaining or differentiating CD34+ cells, emphasizing the importance of CYTL1 in the complex molecular processes that control blood cell development. CYTL1 Protein, Human (HEK293, hFc) is the recombinant human-derived CYTL1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P70794 TSLP Receptor Protein, Human (HEK293, Fc)
TSLP Receptor Protein, a receptor for TSLP, forms a functional complex with IL7R, activating STAT3 and STAT5 for cell proliferation. It also activates JAK2, aiding in hematopoietic system development. TSLP Receptor forms a heterodimer with CRLF2 and IL7R, highlighting its role in intricate signaling pathways crucial for cellular responses and hematopoietic development. TSLP Receptor Protein, Human (HEK293, Fc) is the recombinant human-derived TSLP Receptor protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P78934 CD40L/CD154/TRAP Protein, Human (Biotinylated, HEK293, Fc-Avi)
CD40L/CD154/TRAP proteins stimulate T cell proliferation and cytokine production, acting as ligands for integrins and CD40 receptors to activate various cell-dependent effects such as B cell activation and NF-κ-B signaling. CD40L/CD154/TRAP Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD40L/CD154/TRAP protein, expressed by HEK293 , with N-hFc, N-Avi labeled tag.

Species: Human; Source: HEK293

/
HY-P71910 CD40L/CD154/TRAP Protein, Human (C194W)
CD40L/CD154/TRAP proteins stimulate T cell proliferation and cytokine production, acting as ligands for integrins and CD40 receptors to activate various cell-dependent effects such as B cell activation and NF-κ-B signaling. CD40L/CD154/TRAP Protein, Human (C194W) is the recombinant human-derived CD40L/CD154/TRAP protein, expressed by E. coli , with tag free. The total length of CD40L/CD154/TRAP Protein, Human (C194W) is 149 a.a., with molecular weight of ~16.3 kDa.

Species: Human; Source: E. coli

/
HY-P72907AF Animal-Free CD40L/CD154/TRAP Protein, Human (His)
CD40L/CD154/TRAP proteins stimulate T cell proliferation and cytokine production, acting as ligands for integrins and CD40 receptors to activate various cell-dependent effects such as B cell activation and NF-κ-B signaling. Animal-Free CD40L/CD154/TRAP Protein, Human (His) is the recombinant human-derived animal-FreeCD40L/CD154/TRAP protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

Species: Human; Source: E. coli

/
HY-P70989 TSLP Receptor Protein, Mouse (HEK293, His)
Cytokine receptor-like factor 2 (Crlf2), also known as thymic stromal lymphopoietin (TSLP) receptor, is a receptor for TSLP. Crlf2 can forms a functional complex with TSLP and IL7RA, and overexpression of Crlf2 stimulates cell proliferation through activation of the JAK-STAT pathway. The expression of Crlf2 usually upregulates and mutated in populations of B-progenitor acute lymphoblastic leukemia (B-ALL). TSLP Receptor Protein, Mouse (HEK293, His) is the recombinant mouse-derived TSLP Receptor protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

/
HY-P76300 CYTL1 Protein, Human (HEK293, mFc)
CYTL1 protein is specifically expressed in CD34+ hematopoietic cells, indicating that it exists selectively in this hematopoietic cell subpopulation. This targeted expression pattern suggests a potential role in maintaining or differentiating CD34+ cells, emphasizing the importance of CYTL1 in the complex molecular processes that control blood cell development. CYTL1 Protein, Human (HEK293, mFc) is the recombinant human-derived CYTL1 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Human; Source: HEK293

/
HY-P705242 TSLP Receptor Protein, Human (Biotinylated, HEK293, Fc-Avi)
TSLP Receptor protein is the receptor for TSLP, forming a functional complex with IL7R, activating STAT3 and STAT5 to promote cell proliferation. It also activates JAK2, aiding in hematopoietic system development. The TSLP Receptor forms heterodimers with CRLF2 and IL7R, highlighting its role in a complex signaling pathway crucial for cellular responses and hematopoietic development. The TSLP Receptor Protein, Human (Biotinylated, HEK293, Fc-Avi) is a recombinant biotinylated TSLP Receptor protein expressed by HEK293 and tagged with C-Avi and C-hFc.

Species: Human; Source: HEK293

/
HY-P70823 TSLP Receptor Protein, Mouse (HEK293, Fc)
Cytokine receptor-like factor 2 (Crlf2), also known as thymic stromal lymphopoietin (TSLP) receptor, is a receptor for TSLP. Crlf2 can forms a functional complex with TSLP and IL7RA, and overexpression of Crlf2 stimulates cell proliferation through activation of the JAK-STAT pathway. The expression of Crlf2 usually upregulates and mutated in populations of B-progenitor acute lymphoblastic leukemia (B-ALL). TSLP Receptor Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived TSLP Receptor protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

/
HY-P72121 CD40L/CD154/TRAP Protein, Rhesus macaque (His)
CD40L (CD154; TRAP) is a ligand to CD40/TNFRSF5, acts function by generating a costimulatory signal that up-regulates IL-4 synthesis. CD40L is specifically expressed on activated CD4+ T-lymphocytes and involves in activation of NF-κB/MAPK pathway. CD40L also involves in B cell differentiation, maturation, and apoptosis. CD40L in Rhesus macaque, cleaved into 2 chains of membrane form (1-261 a.a.) and soluble form (113-261 a.a.) which serves as a ligand for integrins (ITGA5:ITGB1 and ITGAV:ITGB3). CD40L/CD154/TRAP Protein, Rhesus macaque (His) has a total length of 218 amino acids (V44-L261), is expressed in E. coli cells with N-terminal 6*His-tag.

Species: Rhesus Macaque; Source: E. coli

/
HY-P77584 CYTL1 Protein, Mouse (HEK293, Fc)
CYTL1 is a cytokine-like protein specifically expressed in bone marrow and cord blood mononuclear cells that bear the CD34 surface marker. CYTL1 exhibits specific expression in CD34+ hematopoietic cells, indicating its selective presence within this subset of cells involved in the regulation of hematopoiesis. CYTL1 regulates chondrogenesis and is required for the maintenance of cartilage homeostasis and, in addition, may act as a regulator of embryo implantation in early pregnancy. CYTL1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CYTL1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

/
HY-P705466 CD40L/CD154/TRAP Trimer Protein, Mouse (HEK293, His-Flag)

Species: Mouse; Source: HEK293

/
HY-P81113 IL-10 Antibody (YA3521)
IL-10 Antibody (YA3521) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-10.

Host: Rabbit; Reactivity: Human

/
HY-P84952 IL-10 Antibody (YA4644)
IL-10 Antibody (YA4644) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-10.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P80328 SOCS2 Antibody (YA072)
SOCS2 Antibody (YA072) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SOCS2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P86311 IL-10 Antibody (YA6003)
IL-10 Antibody (YA6003) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-10.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P811149 CCL5 Antibody
CCL5 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CCL5.

Host: Rabbit; Reactivity: Human, Bovine

/
HY-P85219 IL-10 Antibody (YA4911)
IL-10 Antibody (YA4911) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to IL-10.

Host: Rabbit; Reactivity: Human, Mouse

/
HY-P810855 CD154 Antibody
CD154 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CD154.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P811287 IL-9 Antibody
IL-9 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to IL-9.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P811796 TRAP/CD40L Antibody (YA10267)
TRAP/CD40L Antibody (YA10267) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to TRAP/CD40L.

Host: Rabbit; Reactivity: Human, Mouse

/
HY-P811796A TRAP/CD40L Antibody (YA10267) (PBS only)
TRAP/CD40L Antibody (YA10267) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to TRAP/CD40L.

Host: Rabbit; Reactivity: Human, Mouse

/
HY-P810383 HVEM Antibody (YA9700)
HVEM Antibody (YA9700) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to HVEM.

Host: Rabbit; Reactivity: Human

/
HY-P85469 SOCS-3 Antibody (YA5161)
SOCS-3 Antibody (YA5161) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SOCS-3.

Host: Mouse; Reactivity: Human, Pig

/
HY-P86824 CRLF3 Antibody (YA6517)
CRLF3 Antibody (YA6517) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CRLF3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P87452 IL-9 Antibody (YA7139)
IL-9 Antibody (YA7139) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-9.

Host: Rabbit; Reactivity: Human

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

/

Keywords

cytokine multimerization | cytokine engineering | protein polymer conjugates | receptor clustering | targeted immunotherapy | CD40 ligand